al-335
Small moleculeexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02339207)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- al-335
- al-335
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03277755 | Phase 1 | Sep 11, 2017 | Johnson and Johnson |
| NCT03155893 | Phase 1 | May 12, 2017 | Johnson and Johnson |
| NCT03099135 | Phase 3 | Apr 4, 2017 | Johnson and Johnson |
| NCT03059303 | Phase 1 | Feb 20, 2017 | Johnson and Johnson |
| NCT02993250 | Phase 2 | Dec 21, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02765490 | Phase 2 | Nov 9, 2016 | Johnson and Johnson |
| NCT02894905 | Phase 1 | Sep 13, 2016 | Johnson and Johnson |
| NCT02885454 | Phase 1 | Aug 1, 2016 | Johnson and Johnson |
| NCT02821858 | Phase 1 | Jun 1, 2016 | Johnson and Johnson |
| NCT02824315 | Phase 1 | May 1, 2016 | Johnson and Johnson |
| NCT02569710 | Phase 2 | Oct 31, 2015 | Alios BioPharma |
| NCT02512562 | Phase 1 | Jul 1, 2015 | Achillion Pharmaceuticals, Alios BioPharma |
| NCT02339207 | Phase 1 | Dec 1, 2014 | Alios BioPharma |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 10 | 10 | 3 | 2016 |
| Alios BioPharma | For profit | 3 | 3 | 2 | 2014 |
| Achillion Pharmaceuticals | For profit | 1 | 0 | 1 | 2015 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1